MARKET INTRODUCTION
Liver cancer develops in the liver, also some cancers develop outside liver and some start spreading inside the organ. According to American Cancer Society, in 2019, an estimated 42,030 people were diagnosed with liver cancer in US. Liver cancer represents symptoms such as jaundice, abdominal pain, vomiting, back pain, nausea, and unexplained weight loss. Additionally, type-2 diabetes, family history, heavy alcoholism, and longtime exposure to alfatoxins are some of the risk factors which are responsible to cause liver cancer.
MARKET DYNAMICS
Increasing prevalence of liver cancer is expected to drive the market of liver cancer therapeutics during the forecast period. Additionally, increasing prevalence of risk factors such as diabetes and alcoholism will boost the prevalence of liver cancer, which will in turn drive the growth of the market by 2028.
MARKET SCOPE
The "Liver Cancer Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Liver Cancer Therapeutics Market with detailed market segmentation by liver cancer type, by therapy, and geography. The Liver Cancer Therapeutics Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Liver Cancer Therapeutics Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Liver Cancer Therapeutics Market is segmented on the basis by type and therapy type. Based on liver cancer type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and others. Based on therapy, the market is segmented into targeted therapy, immunotherapy, radiation therapy, chemotherapy, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Liver Cancer Therapeutics Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Liver Cancer Therapeutics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Liver Cancer Therapeutics Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Liver Cancer Therapeutics Market in these regions.
MARKET PLAYERS
The report covers key developments in the Liver Cancer Therapeutics Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Liver Cancer Therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for Liver Cancer Therapeutics Market in the global market. Below mentioned is the list of few companies engaged in the Liver Cancer Therapeutics Market.
The report also includes the profiles of key Liver Cancer Therapeutics Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bristol-Myers Squibb
- Bayer AG
- Merck and Co., Inc.
- Koninklijke Philips N.V
- F. Hoffmann-La Roche Ltd
- Eisai Inc.
- ArQule Inc.
- Celsion Corp.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
LIST OF TABLES
LIST OF FIGURES
The List of Companies
1. Bristol-Myers Squibb
2. Bayer AG
3. Merck and Co., Inc.
4. Koninklijke Philips N.V
5. F. Hoffmann-La Roche Ltd
6. Eisai Inc.
7. ArQule Inc.
8. Celsion Corp.